12 completed, 4 terminated, 1 active not recruiting, 1 recruiting. 20 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 20 | Completed 12, Terminated 4, Active not recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1 |
Follow Fingolimod: new trials by email Literature Review of Fingolimod trials Research Report on Fingolimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fingolimod for Type 2 Diabetes Mellitus Fingolimod, guideline-based treatment for DM - Diabetes Mellitus, Type 2 | Phase 4 | Recruiting | General Hospital of Shenyang Military Region | 40 | 2022-03-15 | 2026-09-10 |
| Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis Fingolimod - Multiple Sclerosis | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 14 | 2020-10-12 | 2026-11-02 |
| A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod Fingolimod - Relapsing Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 382 | 2017-09-19 | 2021-10-07 |
| Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis Fingolimod, Dimethyl Fumarate - Relapsing Remitting Multiple Sclerosis | Phase 4 | Terminated | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | 55 | 2017-04-30 | 2019-10-31 |
| Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01) fingolimod - Relapsing-remitting Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 133 | 2016-05-12 | 2019-02-08 |
| Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants natalizumab, fingolimod - Relapsing-Remitting Multiple Sclerosis | Phase 4 | Terminated | Biogen | 111 | 2014-11-30 | 2017-06-09 |
| Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks Fingolimod - Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 6 | 2014-09-29 | 2021-02-10 |
| Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Fingolimod, Natalizumab - Relapsing Remitting Multiple Sclerosis | Phase 4 | Unknown | University Hospital Muenster | 15 | 2014-03-01 | 2014-12-25 |
| ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon Fingolimod - Multiple Sclerosis | Phase 4 | Withdrawn | Novartis Pharmaceuticals | 2013-06-01 | 2017-04-20 | |
| Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis Fingolimod - Relapsing Remitting Multiple Sclerosis | Phase 4 | Terminated | Heinrich-Heine University, Duesseldorf | 8 | 2013-01-01 | 2016-06-09 |
| A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720 Fingolimod - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Completed | Novartis Pharmaceuticals | 42 | 2012-10-01 | 2016-06-07 |
| A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya® Fingolimod - Relapsing Remitting Multiple Sclerosis RRMS | Phase 4 | Completed | Novartis Pharmaceuticals | 87 | 2012-08-20 | 2020-03-02 |
| Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. Fingolimod, Disease Modifying therapy - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 881 | 2012-06-08 | 2021-01-05 |
| Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) Fingolimod, Interferon beta - 1a (IFN), Glatiramer acetate (GA) - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 298 | 2012-01-01 | 2014-08-08 |
| Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression Venlafaxine, Fluoxetine, Citalopram - Depression, Relapsing-remitting Multiple Sclerosis | Phase 4 | Terminated | Novartis Pharmaceuticals | 54 | 2011-11-01 | 2014-09-25 |
| Fingolimod -Response According to Coping - Evaluation fingolimod - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Completed | Novartis Pharmaceuticals | 189 | 2011-08-01 | 2016-11-18 |
| Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms Fingolimod, Interferon beta 1b - Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 151 | 2011-05-01 | 2017-03-21 |
| Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change Fingolimod, Standard MS DMT - Relapsing Remitting Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 61 | 2011-05-01 | 2015-06-22 |
| Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis Fingolimod - Relapsing-remitting Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 447 | 2011-02-01 | 2016-11-18 |
| A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis Fingolimod, Standard MS DMTs - Relapsing Forms of Multiple Sclerosis | Phase 4 | Completed | Novartis Pharmaceuticals | 1053 | 2010-08-01 | 2014-02-10 |
Multiple Sclerosis, Relapsing-Remitting (14) · Multiple Sclerosis (13) · Anxiety Disorders (1) · Demyelinating Diseases (1) · Depression (1) · Diabetes Mellitus, Type 2 (1) · Motor Activity (1) · Neurobehavioral Manifestations (1)
Novartis Pharmaceuticals (15) · Biogen (1) · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta (1) · General Hospital of Shenyang Military Region (1) · Heinrich-Heine University, Duesseldorf (1) · University Hospital Muenster (1)
Germany (9) · Italy (5) · United States (4) · France (2) · Puerto Rico (2) · Australia (1) · Belgium (1) · Canada (1) · China (1) · Czechia (1) · Russia (1) · Spain (1) · Sweden (1) · Switzerland (1) · Taiwan (1)
Bernd Kieseier, Prof. (1) · HuiSheng Chen, Ph.D (1) · Luisa Klotz, PD. Dr. med. (1) · Renato Mantegazza, MD (1) · Renato Turrini, MD (1)
PMID 23647445, PMID 25424122, PMID 26265273, PMID 26265274, PMID 30050529, PMID 33082194
2017 (1)